These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32840893)

  • 1. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
    Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
    Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
    Yang C; Huang J; Huang X; Huang S; Cheng J; Liao W; Chen X; Wang X; Dai S
    J Crohns Colitis; 2018 Aug; 12(9):1042-1052. PubMed ID: 29762681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
    Subramaniam K; D'Rozario J; Pavli P
    J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
    Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
    Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
    Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.
    Long MD; Martin C; Sandler RS; Kappelman MD
    Aliment Pharmacol Ther; 2013 Feb; 37(4):420-9. PubMed ID: 23240738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.
    Soh JS; Yun WJ; Kim KJ; Won CH; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Kim JH
    Inflamm Bowel Dis; 2015 Apr; 21(4):832-9. PubMed ID: 25789922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
    Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
    Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Shukla T; Singh S; Tandon P; McCurdy JD
    J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases.
    Kobayashi T; Udagawa E; Hibi T
    Digestion; 2022; 103(2):169-173. PubMed ID: 34983046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.